Vectibix panitumumab: Interim Phase IIIb data
Interim 12-week data from the open-label, U.S. Phase IIIb PACCE trial in 500 evaluable patients showed that
Gathering data...
Interim 12-week data from the open-label, U.S. Phase IIIb PACCE trial in 500 evaluable patients showed that